REGENXBIO Preps Investors for Wet AMD Gene Therapy Data Drop
Event summary
- REGENXBIO to host investor event on October 20, 2026, ahead of pivotal data readout for surabgene lomparvovec (sura-vec) in wet AMD
- Event features clinical program overview and perspectives from five leading retina specialists
- Topline pivotal data for sura-vec in wet AMD anticipated in 4Q 2026
- Event will discuss ATMOSPHERE® and ASCENT® pivotal trials and commercial readiness
- Webcast registration available, replay accessible for 30 days post-event
The big picture
REGENXBIO's investor event comes at a critical juncture as it prepares to unveil pivotal data for its gene therapy candidate sura-vec in wet AMD. The company is positioning itself as a leader in AAV gene therapy, with a pipeline that includes treatments for rare and retinal diseases. The event underscores the strategic importance of sura-vec, which is being developed in collaboration with AbbVie, and highlights the unmet need in the wet AMD treatment landscape. The outcomes of the ATMOSPHERE® and ASCENT® trials will be key in determining the therapeutic and commercial potential of sura-vec.
What we're watching
- Data Readout Impact
- How the topline pivotal data for sura-vec in wet AMD will affect REGENXBIO's valuation and strategic positioning in the gene therapy space.
- Commercialization Timeline
- The pace at which REGENXBIO can bring sura-vec to market, given the anticipated data and commercial readiness discussions.
- Competitive Landscape
- Whether REGENXBIO can sustain its lead in gene therapy for retinal diseases amid potential competition from AbbVie and other partners.
Related topics